VIRGINIA RETIREMENT SYSTEMS ET Al Makes New $517,000 Investment in Arrowhead Pharmaceuticals, Inc. $ARWR

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 15,000 shares of the biotechnology company’s stock, valued at approximately $517,000.

Several other large investors also recently modified their holdings of the company. Marex Group plc acquired a new stake in shares of Arrowhead Pharmaceuticals during the 2nd quarter worth approximately $576,000. Marshall Wace LLP boosted its stake in Arrowhead Pharmaceuticals by 3,507.8% during the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock worth $34,065,000 after acquiring an additional 2,096,238 shares in the last quarter. Moody Lynn & Lieberson LLC acquired a new stake in Arrowhead Pharmaceuticals in the second quarter worth $213,000. HBK Sorce Advisory LLC bought a new stake in Arrowhead Pharmaceuticals in the third quarter valued at $2,823,000. Finally, Norges Bank acquired a new position in shares of Arrowhead Pharmaceuticals during the second quarter valued at about $30,414,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Morgan Stanley boosted their target price on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 8th. Bank of America upped their target price on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Royal Bank Of Canada lifted their price target on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a research report on Thursday, December 11th. Finally, HC Wainwright boosted their price target on shares of Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the company a “buy” rating in a research note on Tuesday, December 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $61.89.

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, Director Mauro Ferrari sold 7,530 shares of the stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $70.00, for a total value of $527,100.00. Following the completion of the sale, the director owned 69,053 shares in the company, valued at approximately $4,833,710. This trade represents a 9.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Adeoye Y. Olukotun sold 10,000 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $67.66, for a total transaction of $676,600.00. Following the transaction, the director directly owned 33,600 shares in the company, valued at approximately $2,273,376. This represents a 22.94% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 510,836 shares of company stock worth $33,603,060 in the last ninety days. 4.30% of the stock is owned by corporate insiders.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ:ARWR opened at $63.88 on Tuesday. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.43. The stock has a market cap of $8.68 billion, a PE ratio of -798.40 and a beta of 1.21. The stock’s fifty day simple moving average is $55.20 and its two-hundred day simple moving average is $35.35. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $9.57 and a 1-year high of $72.36.

Arrowhead Pharmaceuticals News Summary

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Health Canada issued a Notice of Compliance for REDEMPLO™ (plozasiran) to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), giving Arrowhead its first approved indication in Canada and creating a near-term commercial foothold and revenue opportunity. Health Canada Approval
• Positive Sentiment: Interim Phase 1/2a data for ARO?INHBE and ARO?ALK7 showed meaningful weight loss and reductions in visceral and total fat and liver measures in obese patients with diabetes — results that de?risk Arrowhead’s obesity/metabolic franchise and broaden mid/long?term upside beyond rare disease assets. Interim Clinical Data
• Positive Sentiment: Analyst sentiment has been improving: several research shops have raised price targets and maintained Buy/Outperform ratings in recent months, supporting higher expectations for stock valuation if approvals and clinical progress continue. Analyst Coverage Summary
• Neutral Sentiment: Institutional ownership remains high (~62.6%), which can amplify moves in either direction; liquidity and analyst coverage are robust, increasing sensitivity to news flow. Institutional Ownership
• Negative Sentiment: A cluster of insider sales has been disclosed recently — including CEO Christopher Anzalone selling 13,187 shares (and a series of prior large disposals) — which may prompt investor caution about insiders monetizing gains even if filings show retained large equity positions. Insider Sales Alert
• Negative Sentiment: Additional insider transactions include sizable sales by James C. Hamilton and COO Patrick O’Brien (SEC forms filed), which could weigh on near?term sentiment even if sales are for diversification or tax planning. SEC Filing (Hamilton)

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.